Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The long-term U.S. study--a report on outcome and tolerance.

R Fleischmann1

  • 1University of Texas, Dallas.

European Journal of Rheumatology and Inflammation
|January 1, 1991
PubMed
Summary

Nabumetone demonstrates long-term safety and efficacy in patients with osteoarthritis and rheumatoid arthritis. Most patients tolerated the anti-inflammatory drug well for up to five years, with similar outcomes across age groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.

RMD open·2020
Same author

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Osteoarthritis and cartilage·2017
Same author

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

Lupus·2017
Same author

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.

Clinical rheumatology·2016
Same author

Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

Arthritis care & research·2016
Same author

Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016

Area of Science:

  • Pharmacology
  • Rheumatology
  • Clinical Trials

Background:

  • Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) used for managing osteoarthritis and rheumatoid arthritis.
  • Long-term data on the efficacy and safety of nabumetone in a large patient cohort are valuable for clinical practice.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of nabumetone in patients with osteoarthritis and rheumatoid arthritis.
  • To assess patient withdrawal rates due to lack of efficacy or adverse effects over a five-year period.
  • To compare outcomes in patients aged over 65 years versus those under 65 years.

Main Methods:

  • 1,912 patients with osteoarthritis or rheumatoid arthritis were enrolled in studies of nabumetone in the United States.
  • Following randomized trials, patients entered an open-label study lasting up to five years.
  • Data on efficacy, adverse effects, and reasons for withdrawal were collected and analyzed.

Main Results:

  • Approximately 25% of patients withdrew due to lack of efficacy, primarily within the first year.
  • Around 12% of patients withdrew due to side effects, also predominantly in the first year.
  • Many patients experienced sustained efficacy and tolerability for the full five years, with no significant differences between age groups.

Conclusions:

  • Nabumetone is a safe and effective anti-inflammatory medication for long-term use in patients with osteoarthritis and rheumatoid arthritis.
  • Withdrawal rates due to efficacy or adverse events were similar in elderly and younger patients.
  • The drug offers a viable long-term treatment option with a manageable safety profile.

Related Experiment Videos